ProKidney Corp. (NASDAQ: PROK) is a clinical-stage biotechnology company focused on developing cell therapy solutions for chronic kidney disease (CKD). Its flagship product, REACT (Renal Autologous Cell Therapy), uses a patient’s own renal cells to restore kidney function and potentially halt CKD progression
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.